Clinical trial · Interventional
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
A Phase 2 Study of Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
NCT06416007CI-TRIAL-00110244recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Locally Advanced | — | UNRESOLVED | — |
| Locally Advanced Carcinoma | Carcinoma | CURATED_BROADER | 0.78 |
| Locally Advanced Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lattice therapy (LRT) | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Lattice radiation therapy (LRT)
- description
- Lattice radiation therapy (LRT) : 5 fractions
- interventionNames
- Radiation: Lattice therapy (LRT)
Primary outcomes (2)
- measure
- Overall Response Rate
- timeFrame
- 60 days post treatment
- description
- To evaluate the efficacy of lattice therapy in patients with bulky tumors, as measured by objective response rate (ORR) at 60 days post-treatment.
- measure
- Adverse Events
- timeFrame
- Up to 60 days post-treatment
- description
- To characterize the safety profile and adverse events (AEs) of lattice therapy.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Solid tumor malignancy with a clinical indication for radiation * Patients must have measurable disease * Target lesion(s) which are amenable to lattice therapy plan * When applicable, target lesion for radiation amenable to immobilization during delivery of radiotherapy * Age ≥18 years. * ECOG Performance status ≤2 * Life expectancy greater than 3 months * Women of child-bearing potential and men must agree to avoid conception via abstinence (ideal) or a method of birth control (e.g., hormonal or barrier method of birth control) prior to study entry and for at least 30 days after completion of lattice therapy administration. * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Patients receiving cytotoxic chemotherapy or known radiosensitizing agents within 5 days before or after lattice therapy. * Patients with hematologic malignancies including lymphoma and leukemia as well as primary or metastatic central nervous system (CNS) malignancies. * Patients with a history of conditions which predispose them to increased radiation toxicity * Patients with known contraindications to radiation therapy * Patients with uncontrolled intercurrent illness * Pregnant women
References
Publications (0)
Data not yet available
No reference posted for this study.